September 3, 2010 by zxuans
Comments (0)
Note that this study has found air 180 that esophageal cancer may be more common in patients taking oral bisphosphonate drugs for long periods. Note also that as pointed out by the editorialist, if causality is proven, the incidence in the population would still be relatively low. Nevertheless, it would be prudent to reinforce recommended directions for taking the product with each prescription. A second look at British registry data indicates that esophageal cancer may be more common after all in 180 air patients taking oral bisphosphonate drugs for long periods.
In a nested case-control analysis involving some 80,000 patients tracked for more than seven years on average, individuals diagnosed with esophageal cancer of were 1.93 times as likely (95% CI 1.37 to 2.70) to have received air max 87 at least 10 prescriptions for oral bisphosphonates, compared with controls not having cancer, reported Jane Green, MD, DPhil, of the University of Oxford in England, and colleagues online in BMJ.
The likelihood of receiving at least one bisphosphonate prescription among esophageal cancer patients was 1.30 (95% CI 1.02 to 1.66) relative to controls, the researchers found. The findings were especially remarkable because air max shoes another research group conducting a case-control study of the same registry -- Great Britain's General Practice Research Database, containing records on some six million patients -- recently reported no increase in esophageal cancer rates in patients treated with bisphosphonates.
Green and colleagues classic max explained the discrepancy by noting that mean observation time prior to diagnosis in the other analysis was substantially shorter, 4.5 versus 7.7 years. Also, they noted, their study used five matched controls for each case, whereas the earlier study had equal numbers of cases and controls. "Our study thus had the potential to include people with longer durations of bisphosphonate use and also fall upon those had greater statistical power," Green and colleagues asserted.
companying editorial by an FDA epidemiologist, Diane Wysowski, PhD, noted that links between bisphosphonates and esophageal cancer have been proposed for more than 15 years. (The editorial carried a disclaimer that it did not necessarily express the agency's official view.) The FDA has collected a total of 68 case slow jam reports of esophageal cancer in patients taking bisphosphonates, half in the U.S. and the rest in Europe and Japan, but has not ordered label warnings. YWJ
